Biocept Inc (BIOC) 2.88 $BIOC
Trade-Ideas: Biocept (BIOC) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Apr 22, 8:45AM CDT
Trade-Ideas LLC identified Biocept (BIOC) as a "dead cat bounce" (down big yesterday but up big today) candidate
BIOC: 2.88 (-0.22)
Most active Nasdaq-traded stocks
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 29.20 (-0.31), AMD: 2.30 (-0.03), FB: 81.53 (-0.88), BIOC: 2.88 (-0.22), CMCSK: 59.19 (+0.50), AXPW: 0.04 (unch), VLTC: 11.54 (+0.50), MSFT: 47.87 (+4.53), INTC: 32.08 (-0.27), AAPL: 130.28 (+0.61), CMCSA: 59.64 (+0.41), CSCO: 28.82 (+0.15)
Will Biocept (BIOC) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:39AM CDT
Will Biocept (BIOC) Continue to Surge Higher?
BIOC: 2.88 (-0.22)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT
HOG: 57.23 (+0.28), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), LRE: 8.69 (+0.11), LRCX: 76.70 (-0.38), MYL: 76.06 (+2.37), NVGN: 6.54 (-0.01), BIOC: 2.88 (-0.22), NBG: 1.23 (+0.06), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04), BCLI: 4.14 (+0.02), SANM: 20.81 (-0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.46 (+0.08), FNRG: 3.11 (-0.86), BIOC: 2.88 (-0.22), NVGN: 6.54 (-0.01), AMPE: 2.73 (-0.16), TRIL: 24.21 (+2.05), CZR: 9.83 (+0.18), TLOG: 4.31 (-0.51), BCLI: 4.14 (+0.02), STDY: 9.95 (-0.19), GENE: 4.70 (-0.13), FARO: 43.44 (-1.22), ICON: 26.77 (unch), XXII: 1.35 (-0.05), XBIT: 22.94 (-4.50), UEC: 2.31 (-0.09), COOL: 1.34 (-0.06), CALA: 13.41 (-0.35), WPCS: 3.72 (-0.10), VIMC: 14.01 (+0.75)
Today's Review on Biotech Equities -- Biocept, Biogen Idec, Kite Pharma, Organovo Holdings, and Bluebird Bio
PR Newswire - Mon Mar 30, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BLUE: 136.26 (-3.82), BIIB: 401.71 (-28.57), KITE: 60.58 (-0.35), ONVO: 5.19 (+0.12), BIOC: 2.88 (-0.22)
Biocept establishes clinical collaboration with Southern Cal-based cancer center
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:03PM CDT
BIOC: 2.88 (-0.22)
Biocept Enters Clinical Collaboration With University of California, San Diego Moores Cancer Center
GlobeNewswire - Tue Mar 24, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that it has entered into a clinical collaboration with University of California, San Diego Moores Cancer Center to determine the clinical utility of detecting biomarkers present in CTCs and ctDNA in blood samples for non-small cell lung cancer patients using Biocept's OncoCEE(TM) LU platform and CEE-Selector(TM) technology.
BIOC: 2.88 (-0.22)
Biocept (BIOC): Today's Weak On High Volume Stock
at The Street - Fri Mar 13, 9:02AM CDT
Trade-Ideas LLC identified Biocept (BIOC) as a weak on high relative volume candidate
BIOC: 2.88 (-0.22)
Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations
GlobeNewswire - Tue Mar 10, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced the launch of its EGFR mutation detection testing utilizing a patient's blood-based liquid biopsy. This innovative diagnostic has the potential to help physicians identify which of their patients may be receptive to certain non-small cell lung cancer treatments.
BIOC: 2.88 (-0.22)
Biocept reports Q4 results
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 3:20PM CDT
BIOC: 2.88 (-0.22)
Biocept Reports Fourth Quarter 2014 Financial Results
GlobeNewswire - Mon Mar 09, 3:05PM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended December 31, 2014.
BIOC: 2.88 (-0.22)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 5.00 (+0.01), ONCY: 0.75 (-0.05), PLUG: 2.65 (-0.02), OCN: 7.74 (-0.15), XON: 44.10 (-0.91), TEDU: 12.84 (+0.03), BIOC: 2.88 (-0.22), LL: 33.07 (-0.58), MNKD: 4.80 (-0.16), CYCC: 0.96 (+0.02), CYTX: 0.99 (+0.01), DATE: 5.90 (+0.11), TSEM: 16.70 (-0.52), LEAF: 52.80 (+0.22), FNJN: 1.39 (-0.06), AMCO: 1.09 (+0.04)
Biocept to Present at the 27th Annual ROTH Conference
GlobeNewswire - Tue Mar 03, 7:31AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 27th Annual ROTH Conference on March 11, 2015 at The Ritz-Carlton Hotel in Laguna Niguel, California.
BIOC: 2.88 (-0.22)
Cost To Borrow Elevated On Biocept
Interactive Brokers - at Seeking Alpha - Mon Mar 02, 2:42PM CST
Cancer diagnostics company Biocept, Inc. (NASDAQ: BIOC ) has received a fair amount of attention in the securities lending space recently. As with similarly sized biotech companies (Biocept currently touts a market-cap of approximately $45mm), the...
BIOC: 2.88 (-0.22)
Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor
GlobeNewswire - Mon Mar 02, 7:35AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced that David Rimm, M.D., Ph.D., Professor of Pathology and Professor of Medicine in Medical Oncology at Yale University School of Medicine, will join the Company as a scientific advisor.
BIOC: 2.88 (-0.22)
Trade-Ideas: Biocept (BIOC) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Apr 22, 8:45AM CDT
Trade-Ideas LLC identified Biocept (BIOC) as a "dead cat bounce" (down big yesterday but up big today) candidate
BIOC: 2.88 (-0.22)
Most active Nasdaq-traded stocks
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 29.20 (-0.31), AMD: 2.30 (-0.03), FB: 81.53 (-0.88), BIOC: 2.88 (-0.22), CMCSK: 59.19 (+0.50), AXPW: 0.04 (unch), VLTC: 11.54 (+0.50), MSFT: 47.87 (+4.53), INTC: 32.08 (-0.27), AAPL: 130.28 (+0.61), CMCSA: 59.64 (+0.41), CSCO: 28.82 (+0.15)
Will Biocept (BIOC) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:39AM CDT
Will Biocept (BIOC) Continue to Surge Higher?
BIOC: 2.88 (-0.22)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT
HOG: 57.23 (+0.28), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), LRE: 8.69 (+0.11), LRCX: 76.70 (-0.38), MYL: 76.06 (+2.37), NVGN: 6.54 (-0.01), BIOC: 2.88 (-0.22), NBG: 1.23 (+0.06), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04), BCLI: 4.14 (+0.02), SANM: 20.81 (-0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.46 (+0.08), FNRG: 3.11 (-0.86), BIOC: 2.88 (-0.22), NVGN: 6.54 (-0.01), AMPE: 2.73 (-0.16), TRIL: 24.21 (+2.05), CZR: 9.83 (+0.18), TLOG: 4.31 (-0.51), BCLI: 4.14 (+0.02), STDY: 9.95 (-0.19), GENE: 4.70 (-0.13), FARO: 43.44 (-1.22), ICON: 26.77 (unch), XXII: 1.35 (-0.05), XBIT: 22.94 (-4.50), UEC: 2.31 (-0.09), COOL: 1.34 (-0.06), CALA: 13.41 (-0.35), WPCS: 3.72 (-0.10), VIMC: 14.01 (+0.75)
Today's Review on Biotech Equities -- Biocept, Biogen Idec, Kite Pharma, Organovo Holdings, and Bluebird Bio
PR Newswire - Mon Mar 30, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BLUE: 136.26 (-3.82), BIIB: 401.71 (-28.57), KITE: 60.58 (-0.35), ONVO: 5.19 (+0.12), BIOC: 2.88 (-0.22)
Biocept establishes clinical collaboration with Southern Cal-based cancer center
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:03PM CDT
BIOC: 2.88 (-0.22)
Biocept Enters Clinical Collaboration With University of California, San Diego Moores Cancer Center
GlobeNewswire - Tue Mar 24, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that it has entered into a clinical collaboration with University of California, San Diego Moores Cancer Center to determine the clinical utility of detecting biomarkers present in CTCs and ctDNA in blood samples for non-small cell lung cancer patients using Biocept's OncoCEE(TM) LU platform and CEE-Selector(TM) technology.
BIOC: 2.88 (-0.22)
Biocept (BIOC): Today's Weak On High Volume Stock
at The Street - Fri Mar 13, 9:02AM CDT
Trade-Ideas LLC identified Biocept (BIOC) as a weak on high relative volume candidate
BIOC: 2.88 (-0.22)
Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations
GlobeNewswire - Tue Mar 10, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced the launch of its EGFR mutation detection testing utilizing a patient's blood-based liquid biopsy. This innovative diagnostic has the potential to help physicians identify which of their patients may be receptive to certain non-small cell lung cancer treatments.
BIOC: 2.88 (-0.22)
Biocept reports Q4 results
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 3:20PM CDT
BIOC: 2.88 (-0.22)
Biocept Reports Fourth Quarter 2014 Financial Results
GlobeNewswire - Mon Mar 09, 3:05PM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended December 31, 2014.
BIOC: 2.88 (-0.22)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 5.00 (+0.01), ONCY: 0.75 (-0.05), PLUG: 2.65 (-0.02), OCN: 7.74 (-0.15), XON: 44.10 (-0.91), TEDU: 12.84 (+0.03), BIOC: 2.88 (-0.22), LL: 33.07 (-0.58), MNKD: 4.80 (-0.16), CYCC: 0.96 (+0.02), CYTX: 0.99 (+0.01), DATE: 5.90 (+0.11), TSEM: 16.70 (-0.52), LEAF: 52.80 (+0.22), FNJN: 1.39 (-0.06), AMCO: 1.09 (+0.04)
Biocept to Present at the 27th Annual ROTH Conference
GlobeNewswire - Tue Mar 03, 7:31AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 27th Annual ROTH Conference on March 11, 2015 at The Ritz-Carlton Hotel in Laguna Niguel, California.
BIOC: 2.88 (-0.22)
Cost To Borrow Elevated On Biocept
Interactive Brokers - at Seeking Alpha - Mon Mar 02, 2:42PM CST
Cancer diagnostics company Biocept, Inc. (NASDAQ: BIOC ) has received a fair amount of attention in the securities lending space recently. As with similarly sized biotech companies (Biocept currently touts a market-cap of approximately $45mm), the...
BIOC: 2.88 (-0.22)
Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor
GlobeNewswire - Mon Mar 02, 7:35AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced that David Rimm, M.D., Ph.D., Professor of Pathology and Professor of Medicine in Medical Oncology at Yale University School of Medicine, will join the Company as a scientific advisor.
BIOC: 2.88 (-0.22)
